NCT07326371

Glofitamab Combined With CAR-T Therapy in R/R DLBCL

A Single-Center, Prospective Study Evaluating the Efficacy and Safety of Glofitamab Combined With CAR-T Therapy in Patients With High-Risk Relapsed/Refractory Large B-Cell Lymphoma

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: Ruijin Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is a single-center, open-label, prospective study aimed at evaluating the efficacy and safety of Glofitamab combined with CAR-T therapy in patients with high-risk relapsed/refractory large B-cell lymphoma.

Conditions

• DLBCL - Diffuse Large B Cell Lymphoma

Interventions

Type	Name	Description
DRUG	Glofitamab	Glofitamab IV infusion will be administered as per the schedule specified in the respective arm.
DRUG	Obinutuzumab	Obinutuzumab IV infusion will be administered as per the schedule specified in the respective arm.
DRUG	Axicabtagene Ciloleucel	Axicabtagene Ciloleucel IV infusion will be administered as per the schedule specified in the respective arm.
DRUG	Relmacabtagene autoleucel (relma-cel)	Relmacabtagene autoleucel IV infusion will be administered as per the schedule specified in the respective arm.

Timeline

• Start date: 2026-03-01
• Primary completion: 2027-07-01
• Completion: 2029-03-01
• First posted: 2026-01-08
• Last updated: 2026-01-08